Pharma marketing agency serving Dallas-Fort Worth and the US
Ichelon Consulting US operates a pharma marketing practice out of Dallas, TX 75220 for branded and generic manufacturers, specialty pharmacies, and pharma-adjacent digital health companies across the United States. Every deliverable — website, campaign, HCP portal, patient site — is scoped against FDA promotional rules, DSCSA obligations and MLR-review workflows from the first draft.
- Ichelon Consulting US runs pharma campaigns against FDA promotional rules, DSCSA obligations, OIG-EIG anti-kickback lines and state Rx advertising laws from first draft to final publish.
- Every asset flows through a client's MLR review workflow — Medical, Legal, Regulatory — with change tracking and version control at the asset level.
- HCP-vs-patient content walls are engineered in — separate portals, separate consent flows, separate ad audiences, separate keyword universes.
- Accounts are run by the US client team in Dallas on Central Time, with USD contracts from the US LLC. Production comes from ICG's specialist production team in Gurugram, part of the same company.
- Dallas, Texas LLC
- US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
Six pharma marketing services tailored to US manufacturers
Pharma marketing runs on different physics than general healthcare marketing. The audience is bifurcated (HCP vs patient), the content is regulated (fair balance, ISI, black box warnings), the sales cycle is long (six to eighteen months for a rep-detailed brand), and every asset has to survive MLR. Our six-service delivery spine is built for that reality.
1. HCP-facing SEO and content hubs
Peer-reviewed clinical content architected for HCP intent — mechanism-of-action pages, prescribing information portals, dosing calculators, drug-interaction references. Gated access, HCP-only ad targeting, DEA-aware disclosure surfaces.
2. Patient-facing DTC campaigns
DTC websites, unbranded disease-awareness campaigns, patient support programs, adherence content — all with fair-balance ISI, appropriate use statements, and CAN-SPAM-safe email nurture. Consent architecture segregates patient and HCP audiences.
3. MLR-friendly asset production
Every asset — banner, landing page, video, email, sales aid — is delivered in a format that plugs directly into the client's MLR review platform. Version-locked references, footnoted claims, and change tracking at the copy-block level.
4. Meta Ads for pharmacovigilance-friendly audiences
Meta and search campaigns that respect pharmacovigilance reporting obligations — AE-monitoring workflows for every comment, message and form, with SOP-defined escalation to the client's pharmacovigilance team within the required timeframe.
5. Congress, symposium and KOL content
Pre-congress SEO, symposium recap content, KOL video interviews, post-congress email nurture. Coordinated across HCP portals, LinkedIn and email — all MLR-cleared and OIG-EIG-line-safe.
6. DSCSA and state Rx compliance overlay
Product traceability, state-level Rx advertising rules, and OIG-EIG anti-kickback boundary work built into every promotional asset. State-by-state matrix maintained for the jurisdictions the brand ships to.
Practice serving these DFW cities
Ichelon Consulting US is anchored in Dallas, TX 75220 and delivers to pharma clients across the North Texas metroplex — including specialty pharmacies, biotech companies and pharma-adjacent digital health firms.
Every pharma asset is scoped against these frameworks before MLR
Angryturtle · SIE · YODA — the pharma version
Pharma is not a walk-in category, but branded search intent, HCP research intent and patient adherence intent all matter. The Trifecta covers all three surfaces — with MLR-friendly asset packaging built into the delivery workflow.
Angryturtle · GBP OS
Deployed for pharmacy-facing brand locations, patient support program offices and injectable-training centres. Post cadence, review response, HCP-safe Q&A seeding.
SIE · Search Intelligence Engine
Topic map covering condition, mechanism of action, and prescribing intent — with fair-balance ISI wrapped into every content brief. AI Overview appearance monitored weekly.
YODA · YouTube AIO
KOL interviews, MoA explainers, patient-adherence content — MLR-cleared with locked references. Optimised for AI Overview citations and YouTube's own health surfaces.
Backed by ICG global leadership
Pharma engagements have direct line-of-sight to the ICG Leadership Team and to a senior editorial reviewer who has shipped MLR-cleared work before.
Our own tools run inside every engagement
Ichelon Consulting US uses software built by our own product team. Practices can also use most tools on their own, billed in USD.
Pharma marketing in the US — common questions
Do you plug into our MLR review platform?
Yes. Every asset is delivered in a format that plugs directly into your MLR platform — version-locked references, footnoted claims, change tracking at the copy-block level. We have shipped work through the common enterprise MLR tools without adding review cycles.
How do you separate HCP and patient audiences?
Separate portals, separate consent flows, separate ad audiences, separate keyword universes. HCP portals sit behind NPI verification or NPPES lookup; patient portals surface unbranded disease-awareness content with fair-balance ISI where required.
What is your pharmacovigilance workflow for AE reports?
Every organic and paid channel we run has an AE-monitoring SOP. Any comment, message, form, review or DM that reads as an adverse event report is escalated to your pharmacovigilance team within your specified timeframe, in the format your team requires.
Can you run branded search alongside unbranded disease-awareness?
Yes — with strict separation. Branded search sits under one campaign structure with full ISI on landing pages; unbranded disease-awareness sits under a separate structure, with no brand mention on assets or in ad copy, and separate remarketing lists.
Do you cover DSCSA obligations in promotional content?
Yes. Product identifier, lot number and expiration date requirements from DSCSA are referenced accurately in promotional content where relevant, and traceability language is scoped against the client's supply chain SOP.
What is a typical pharma engagement cost?
Retainers are custom-scoped per engagement · from $499/month. Pharma engagements typically sit higher than the floor because of the MLR review overhead and the HCP-vs-patient wall architecture.
Scope your US pharma engagement with Ichelon Consulting US
Book a 30-minute benchmarking call with a member of the Leadership Team, email the US practice lead, or WhatsApp us in your time zone.
Ichelon Consulting US in the US — other industries
Common questions
What's the difference between general digital marketing agencies and ones that specialize in pharmaceutical and life sciences, and why does vertical expertise matter?
Specialist pharma agencies work inside FDA promotion rules: fair balance, Important Safety Information, no off-label claims, and medical-legal-regulatory (MLR) review before anything goes live. They also run adverse event reporting workflows, keep HCP and patient audiences separate, and know platform restrictions on prescription drugs. A general agency may produce strong creative but often stalls in MLR review, delaying launches.
How do you advertise to doctors (HCP marketing)?
HCP marketing reaches doctors through channels they already use: NPI-targeted digital and programmatic ads, medical journals and websites, congress sponsorships, peer-to-peer programs, rep-triggered email and gated HCP-only websites. Content must follow FDA promotional rules, including fair balance and on-label claims, and payments or transfers of value to physicians are reported under the Sunshine Act's Open Payments program.